Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.43 |
| ▸ | RELA | Q04206 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31157940 | 0.86 | MAPT (0.45) | MAPTNPC1RAB9AMAPK1NFKB1 | |
| SCHEMBL25027874 | 0.84 | PIK3CA (0.39) | RAB9AMEN1KMT2AALDH1A1POLB | |
| SCHEMBL31157926 | 0.84 | PIK3CA (0.39) | RAB9AMEN1KMT2AALDH1A1POLB | |
| SCHEMBL23926961 | 0.78 | L3MBTL1 (0.48) | MAPTNPC1RAB9AMAPK1MEN1 | |
| SCHEMBL30079634 | 0.78 | L3MBTL1 (0.48) | MAPTNPC1RAB9AMAPK1MEN1 | |
| SCHEMBL13721447 | 0.77 | MAPT (0.58) | MAPTNPC1RAB9AMAPK1MEN1 | |
| SCHEMBL6347219 | 0.75 | MEN1 (0.62) | MAPTNPC1RAB9AMAPK1NFKB1 | |
| SCHEMBL31157947 | 0.74 | MAPT (0.44) | MAPTNPC1RAB9AMAPK1NFKB1 | |
| SCHEMBL13730771 | 0.74 | MAPT (0.50) | MAPTNPC1RAB9AMAPK1NFKB1 | |
| SCHEMBL23927045 | 0.74 | MAPT (0.46) | MAPTNPC1RAB9AMAPK1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327406-A1 | POTASSIUM CHANNEL MODULATORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327406-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNN2, KCNN1 | MAPT 1029/4885NPC1 449/4885RAB9A 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.